- Home
- SB vs ATYR Comparison
SB vs ATYR Comparison
Compare SB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- ATYR
- Stock Information
- Founded
- SB 2007
- ATYR 2005
- Country
- SB Monaco
- ATYR United States
- Employees
- SB N/A
- ATYR N/A
- Industry
- SB Marine Transportation
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SB Consumer Discretionary
- ATYR Health Care
- Exchange
- SB Nasdaq
- ATYR Nasdaq
- Market Cap
- SB 423.6M
- ATYR 451.3M
- IPO Year
- SB 2008
- ATYR 2015
- Fundamental
- Price
- SB $4.25
- ATYR $4.90
- Analyst Decision
- SB Strong Buy
- ATYR Strong Buy
- Analyst Count
- SB 1
- ATYR 6
- Target Price
- SB $5.00
- ATYR $20.20
- AVG Volume (30 Days)
- SB 406.1K
- ATYR 6.1M
- Earning Date
- SB 07-29-2025
- ATYR 08-07-2025
- Dividend Yield
- SB 4.71%
- ATYR N/A
- EPS Growth
- SB N/A
- ATYR N/A
- EPS
- SB 0.43
- ATYR N/A
- Revenue
- SB $277,509,000.00
- ATYR N/A
- Revenue This Year
- SB N/A
- ATYR $551.06
- Revenue Next Year
- SB $13.41
- ATYR $1,874.58
- P/E Ratio
- SB $9.84
- ATYR N/A
- Revenue Growth
- SB N/A
- ATYR N/A
- 52 Week Low
- SB $3.02
- ATYR $1.67
- 52 Week High
- SB $5.24
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- SB 60.36
- ATYR 44.49
- Support Level
- SB $4.12
- ATYR $4.47
- Resistance Level
- SB $4.30
- ATYR $5.75
- Average True Range (ATR)
- SB 0.13
- ATYR 0.40
- MACD
- SB 0.01
- ATYR -0.05
- Stochastic Oscillator
- SB 87.67
- ATYR 24.93
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.